BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungar B, Malickova K, Hanžel J, Abu-Arisha M, Paul S, Rocha C, Ben-Shatach Z, Abitbol CM, Haj-Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben-Horin S. Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms. J Crohns Colitis 2021:jjab067. [PMID: 33837762 DOI: 10.1093/ecco-jcc/jjab067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hanzel J, Dreesen E, Vermeire S, Löwenberg M, Hoentjen F, Bossuyt P, Clasquin E, Baert FJ, D'Haens GR, Mathôt R. Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. Inflamm Bowel Dis 2021:izab143. [PMID: 34137430 DOI: 10.1093/ibd/izab143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Vaughn BP. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease. J Clin Med 2021;10:4990. [PMID: 34768509 DOI: 10.3390/jcm10214990] [Reference Citation Analysis]
3 Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-biroulet L. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology & Hepatology 2022;7:171-85. [DOI: 10.1016/s2468-1253(21)00223-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
4 Vande Casteele N, Sandborn WJ, Feagan BG, Vermeire S, Dulai PS, Yarur A, Roblin X, Ben-Horin S, Dotan I, Osterman MT, Rosario M, Osborn TM, Panes J, Lindner D, Agboton C. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther 2022. [PMID: 35474325 DOI: 10.1111/apt.16937] [Reference Citation Analysis]